Stephen K. Brannan

8.5k total citations · 5 hit papers
69 papers, 6.2k citations indexed

About

Stephen K. Brannan is a scholar working on Psychiatry and Mental health, Molecular Biology and Pharmacology. According to data from OpenAlex, Stephen K. Brannan has authored 69 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Psychiatry and Mental health, 15 papers in Molecular Biology and 15 papers in Pharmacology. Recurrent topics in Stephen K. Brannan's work include Schizophrenia research and treatment (18 papers), Treatment of Major Depression (14 papers) and Receptor Mechanisms and Signaling (9 papers). Stephen K. Brannan is often cited by papers focused on Schizophrenia research and treatment (18 papers), Treatment of Major Depression (14 papers) and Receptor Mechanisms and Signaling (9 papers). Stephen K. Brannan collaborates with scholars based in United States, United Kingdom and Germany. Stephen K. Brannan's co-authors include Helen S. Mayberg, Janet L. Tekell, Peter T. Fox, Roderick K. Mahurin, Charles Martin, Paul Jerabek, Scott McGinnis, Jack L. Lancaster, Mario Liotti and Mark S. George and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Stephen K. Brannan

64 papers receiving 6.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reciprocal Limbic-Cortical Function and Negative Mood: Converging PET Findings in Depression and Normal Sadness

1999 1.9k citations Stephen K. Brannan et al. American Journal of Psychiatry profile →
Cingulate function in depression

1997 832 citations Stephen K. Brannan et al. profile →
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

2021 216 citations Stephen K. Brannan, Sharon Sawchak et al. profile →
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

2023 104 citations Inder Kaul, Sharon Sawchak et al. The Lancet profile →
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia

2024 71 citations Inder Kaul, Sharon Sawchak et al. profile →

Peers

Countries citing papers authored by Stephen K. Brannan

Since Specialization

Citations

This map shows the geographic impact of Stephen K. Brannan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen K. Brannan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen K. Brannan more than expected).

Fields of papers citing papers by Stephen K. Brannan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen K. Brannan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen K. Brannan. The network helps show where Stephen K. Brannan may publish in the future.

Co-authorship network of co-authors of Stephen K. Brannan

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen K. Brannan. A scholar is included among the top collaborators of Stephen K. Brannan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen K. Brannan. Stephen K. Brannan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial 2026 ·American Journal of Psychiatry ·Inder Kaul, Amy Claxton, Colin Sauder, (unknown), (unknown), (unknown), (unknown), (unknown), Sharon Sawchak, Stephen K. Brannan	1
2	SAFETY AND EFFICACY OF KARXT IN PATIENTS WITH SCHIZOPHRENIA IN THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS 2025 ·The International Journal of Neuropsychopharmacology ·Kenneth L. Kramer, Stephen K. Brannan, Colin Sauder, Inder Kaul	1
3	Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia 2025 ·The Journal of Clinical Psychiatry ·Inder Kaul, Amy Claxton, Sharon Sawchak, Colin Sauder, Stephen K. Brannan, (unknown), (unknown), (unknown), David T. Brown, Andrew J. Cutler, Ronald N. Marcus	4
4	Long-term Safety of KarXT (Xanomeline and Trospium) in Schizophrenia 2024 ·Neuroscience Applied ·(unknown), R. Marcus, Ramesh K. Kakar, Amy Claxton, Stephen K. Brannan, Inder Kaul	1
5	Safety and Tolerability of KarXT (Xanomeline Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials 2024 ·CNS Spectrums ·Stephen K. Brannan, Andrew J. Cutler, Sharon Sawchak, Judith C. Kando, Andrew Miller, Amy Claxton, Steven M. Paul, Inder Kaul	1
6	Maintenance of Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia 2024 ·Neuroscience Applied ·Karl W. Krämer, Inder Kaul, (unknown), Amy Claxton, Stephen K. Brannan	2
7	414. Understanding the Role of Muscarinic M1 and M4 Receptors in Neural Circuits That Modulate Negative Symptoms of Schizophrenia 2024 ·Biological Psychiatry ·Samantha E. Yohn, William P. Horan, Stephen K. Brannan, Steven M. Paul	1
8	Muscarinic Receptor Activators as Novel Treatments for Schizophrenia 2024 ·Biological Psychiatry ·S. Paul, Samantha E. Yohn, Stephen K. Brannan, Nichole M. Neugebauer‎, Alan Breier	20
9	Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials 2024 ·SHILAP Revista de lepidopterología ·Inder Kaul, Sharon Sawchak, Amy Claxton, Colin Sauder, (unknown), Rishi Kakar, David P. Walling, Leslie Citrome, Haiyuan Zhu, Andrew Miller, Stephen K. Brannan	13
10	Safety and efficacy of KarXT (Xanomeline Trospium) in Schizophrenia in the Phase 3, Randomized, Double-Blind, Placebo-Controlled EMERGENT-2 Trial 2023 ·CNS Spectrums ·Christoph U. Correll, Andrew C. Miller, Sharon Sawchak, Inder Kaul, Steven M. Paul, Stephen K. Brannan	8
11	Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results 2023 ·Psychopharmacology ·Alan Breier, Stephen K. Brannan, Steven M. Paul, Andrew Miller	40
12	Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial breakdown → 2023 ·The Lancet ·Inder Kaul, Sharon Sawchak, Christoph U. Correll, Rishi Kakar, Alan Breier, Haiyuan Zhu, Andrew Miller, Steven M. Paul, Stephen K. Brannan	104
13	Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial 2021 ·Journal of Psychiatric Research ·Steven D. Targum, Christopher F. Murphy, Alan Breier, Stephen K. Brannan	4
14	Using Genetics to Enable Studies on the Prevention of Alzheimer’s Disease 2012 ·Clinical Pharmacology & Therapeutics ·Donna G. Crenshaw, William Gottschalk, Michael W. Lutz, I. Grossman, Ann M. Saunders, James R. Burke, Kathleen A. Welsh‐Bohmer, Stephen K. Brannan, Daniel K. Burns, Allen D. Roses	59
15	Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine 2008 ·International Clinical Psychopharmacology ·Madhukar H. Trivedi, D. Desaiah, (unknown), Yili Pritchett, Stephen K. Brannan, Michael J. Detke	49
16	Making clinicians lives easier: Guidance on use of the QIDS self-report in place of the MADRS 2006 ·Journal of Affective Disorders ·Thomas Carmody, A. John Rush, Ira H. Bernstein, Stephen K. Brannan, Mustafa M. Husain, Madhukar H. Trivedi	34
17	Vagus Nerve Stimulation for Treatment-Resistant\nDepression: A Randomized, Controlled Acute\nPhase Trial 2005 ·Insecta mundi ·A. John Rush, Lauren B. Marangell, Harold A. Sackeïm, Mark S. George, Stephen K. Brannan, Sonia M. Davis, Robert H. Howland, Mitchel A. Kling, Barry R. Rittberg, W. J. Burke, Mark Hyman Rapaport, John Zajecka, Andrew A. Nierenberg, Mustafa M. Husain, David Ginsberg, R.G. Cooke	416
18	Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial 2005 ·Biological Psychiatry ·A. John Rush, Lauren B. Marangell, Harold A. Sackeïm, Mark S. George, Stephen K. Brannan, Sonia M. Davis, Robert H. Howland, Mitchel A. Kling, Barry R. Rittberg, W. J. Burke, Mark Hyman Rapaport, John Zajecka, Andrew A. Nierenberg, Mustafa M. Husain, David Ginsberg, R.G. Cooke	18
19	Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study 2005 ·Biological Psychiatry ·A. John Rush, Harold A. Sackeïm, Lauren B. Marangell, Mark S. George, Stephen K. Brannan, Sonia M. Davis, Phil Lavori, Robert H. Howland, Mitchel A. Kling, Barry R. Rittberg, Linda L. Carpenter, Philip T. Ninan, Francisco Moreno, Sonia Thomas, Charles R. Conway, Michael J. Burke, John J. Barry	270
20	Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder 2004 ·Journal of Psychiatric Research ·Stephen K. Brannan, Craig Mallinckrodt, Eileen B. Brown, Madelaine M. Wohlreich, John G. Watkin, Alan F. Schatzberg	149

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact